In vivo activities of ceftriaxone and 46vancomycin against Borrelia spp in the mouse brain and other sites.

 Antimicrob Agents Chemother. 1996 Nov;40 11 :2632-6.In vivo activities of ceftriaxone and 
46vancomycin against Borrelia spp in the mouse brain and other sites. Kazragis RJ, Dever LL, 
Jorgensen JH, Barbour AG.
Department of Medicine Infectious Diseases, University of Texas Health Science Center at San 
Antonio 78284, USA.
Borrelia burgdorferi, the agent of Lyme disease, and B. turicatae, a neurotropic agent of 
relapsing fever, are susceptible to vancomycin in vitro, with an MIC of 0.5 microgram/ml. To 
determine the activity of vancomycin in vivo, particularly in the brain, we infected adult 
immunocompetent BALB/c and immunodeficient CB-17 scid mice with B. burgdorferi or B. 
turicatae. The mice were then treated with vancomycin, ceftriaxone as a positive control, or 
normal saline as a negative control. The effectiveness of treatment was assessed by cultures of 
blood and brain and other tissues. Ceftriaxone at a dose of 25 mg/kg of body weight administered 
every 12 h for 7 to 10 days eliminated cultivable B. burgdorferi or B. turicatae from all BALB/c or 
scid mice in the study.Vancomycin at 30 mg/kg administered every 12 h was effective in 
eliminating infection from immunodeficient mice if treatment was started within 3 days of 
the onset of infection. If treatment with vancomycin was delayed for 7 days or more, 
vancomycin failed to eradicate infection with B. burgdorferi or B. turicatae from 
immunodeficient mice. The failure of vancomycin in eradicating established infections in 
immunodeficient mice was associated with the persistence of viable spirochetes in the brain 
during antibiotic treatment




Share This
Pin on PinterestShare on FacebookTweet about this on TwitterShare on StumbleUponShare on Google+

Leave a Reply

Your email address will not be published.